Page last updated: 2024-10-20

succinic acid and Coronary Disease

succinic acid has been researched along with Coronary Disease in 5 studies

Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851)
succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.

Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19903 (60.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
SUBERVIOLA, J1
GALANTE, GD1
CINTAS, JA1
Bittl, JA1
Shine, KI1
Muscari, C1
Turinetto, B1
Colì, G1
Galeazzi, M1
Cattabriga, I1
Finelli, C1
Biagetti, L1
Guarnieri, C1
Caldarera, CM1
Ueta, H1
Ogura, R1
Sugiyama, M1
Kagiyama, A1
Shin, G1
Onishchenko, NA1
Lubiako, AA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827]Phase 3865 participants (Actual)Interventional2005-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Atrial Fibrillation

Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay

InterventionParticipants (Count of Participants)
Intravenous Glutamate147
Saline Infusion152

ICU Stay

ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay

Interventionhours (Median)
Intravenous Glutamate21
Saline Infusion21

Number of Participants With Perioperative Myocardial Infarction, Postoperative Heart Failure or Postoperative Mortality

(NCT00489827)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Intravenous Glutamate31
Saline Infusion25

Number of Participants With Postoperative Stroke < 24 Hours

Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Intravenous Glutamate4
Saline Infusion6

Postoperative Hemodynamic State in Patients With Severely Reduced Left Ventricular Ejection Fraction (LVEF<0.40)

Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery

InterventionParticipants (Count of Participants)
Intravenous Glutamate1
Saline Infusion5

Postoperative Renal Function

maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days

Interventionµmol/L (Mean)
Intravenous Glutamate106
Saline Infusion106

Severe Circulatory Failure in CCS Class IV Patients

Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Intravenous Glutamate3
Saline Infusion16

Degree of Perioperative Myocardial Injury

p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative

,
Interventionµg/L (Median)
CK-MB day 1Troponin-T day 3
Intravenous Glutamate140.27
Saline Infusion140.24

Postoperative Hemodynamic State

Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU

,
Interventionpercentage of saturated hemoglobin (Mean)
SvO2 at weaning from CPBSvO2 on arrival to ICU
Intravenous Glutamate72.065.0
Saline Infusion72.264.9

Other Studies

5 other studies available for succinic acid and Coronary Disease

ArticleYear
[The action of succinic acid in chronic coronary insufficiency].
    Prensa medica argentina, 1953, Jun-12, Volume: 40, Issue:24

    Topics: Anti-Arrhythmia Agents; Cardiotonic Agents; Coronary Disease; Diuretics; Humans; Succinates; Succini

1953
Protection of ischemic rabbit myocardium by glutamic acid.
    The American journal of physiology, 1983, Volume: 245, Issue:3

    Topics: Adenosine Triphosphate; Animals; Blood Pressure; Coronary Disease; Coronary Vessels; Glutamates; Glu

1983
Changes in myocardial mitochondrial respiration after ligation of the coronary artery in pigs.
    Cardioscience, 1990, Volume: 1, Issue:4

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cell Fractionation; Coronary Disease; Corona

1990
O2-. spin trapping on cardiac submitochondrial particles isolated from ischemic and non-ischemic myocardium.
    Journal of molecular and cellular cardiology, 1990, Volume: 22, Issue:8

    Topics: Animals; Cattle; Coronary Disease; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Free Radic

1990
[Anti-ischemic protection of the myocardium by cardioplegic solutions].
    Vestnik Akademii meditsinskikh nauk SSSR, 1985, Issue:4

    Topics: Animals; Coronary Disease; Dogs; Heart Arrest, Induced; Magnesium; Magnesium Chloride; Potassium Chl

1985